drugset / Trial / NCT00853606

Long-Term Safety and Efficacy Study of Avanafil in Men With Erectile Dysfunction

NCT00853606

Phase 3 Completed 712 enrolled VIVUS LLC
NaSingle-groupOpen-labelTreatment

Summary

This open-label study is being conducted to evaluate the long-term safety, tolerability, and efficacy of avanafil in men with mild to severe erectile dysfunction. Approximately 400 subjects will be enrolled and treated with avanafil for up to 52 weeks.

Timeline

Start
2009-03
Primary completion
2010-04
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Avanafil Small molecule 50 mg
Subject Avanafil Small molecule 100 mg
Subject Avanafil Small molecule 200 mg

Indications